All contributors
Onconephrology contributor
Sise, Meghan E
Primarily Anticancer drug nephrotoxicity#28 of 47 recognizedHonor roll
- #2 in Checkpoint-inhibitor kidney injury
30
Clinical papers
1,468
Citations (iCite)
2 / 17
First / senior author
2019–2025
Active years
Output over time
Clinical corpus papers per year — peak 7 in 2021.
- 2019: 3 papers
- 2020: 3 papers
- 2021: 7 papers
- 2022: 6 papers
- 2023: 5 papers
- 2024: 2 papers
- 2025: 4 papers
20192025
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Anticancer drug nephrotoxicity19
Checkpoint-inhibitor kidney injury16
Onco-nephrology (general)6
Cellular therapy renal effects3
Anti-VEGF / TKI renal effects1
Frequent collaborators
Other recognized contributors who most often share corpus papers with Sise (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Sise among the leading contributors.
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.